A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations.
Acta Med Indones
; 43(1): 39-52, 2011 Jan.
Article
en En
| MEDLINE
| ID: mdl-21339545
ABSTRACT
AIM:
to assess the effects of thiazolidinediones (pioglitazone and rosiglitazone) in the treatment of T2DM in Asian population.METHODS:
randomized controlled trials of T2DM patients in Asian population that compared pioglitazone or rosiglitazone with other treatments for more than 3 months and reported HbA1c data were included. Analyses for all outcomes were calculated using random effect model.RESULTS:
the analyses included 37 studies in approximately 3,000 patients. Thiazolidinediones had beneficial effect on HbA1c (glycosylated hemoglobin/hemoglobin A1c) compared with control (weighted mean difference (WMD) -0.12%; 95% CI [confidence interval], -0.54 to -0.19% for pioglitazone and -0.47%; 95% CI, -0.89 to -0.40% for rosiglitazone). Overall, TZDs showed significant benefit on glycemic outcomes measured by HbA1c as main surrogate outcome compared with previous glycemic control but not with other anti-diabetics.CONCLUSION:
thiazolidinediones treatment resulted in favorable effects on glycemic control in Asian patients with T2DM. Long-term efficacy and safety data of TZD could not yet be confirmed due to the lack of randomized studies with patient-oriented outcomes.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tiazolidinedionas
/
Pueblo Asiatico
/
Diabetes Mellitus Tipo 2
/
Hipoglucemiantes
Tipo de estudio:
Clinical_trials
/
Prevalence_studies
/
Risk_factors_studies
/
Systematic_reviews
Límite:
Female
/
Humans
/
Male
País/Región como asunto:
Asia
Idioma:
En
Revista:
Acta Med Indones
Año:
2011
Tipo del documento:
Article
País de afiliación:
Indonesia